BERLIN (Reuters) - German kidney dialysis provider Fresenius Medical
Care (FMC) said it is challenging a U.S. move to end assistance to
patients with end-stage renal disease (ESRD) that it said could have
a "material adverse affect" on its business.
FMC said it and other providers and patient advocates had filed a
lawsuit challenging the rulemaking process and seeking to stop the
new regulation, which it said is due to take effect on Jan. 13.
It said in a statement that the new regulation could put an end to
assistance programmes that help fund health insurance premiums for
patients with ESRD, with between 700 and 2,000 FMC patients
FMD said it could suffer a "material adverse effect on our business"
if the regulation does become effective, along with efforts by
insurers to reject premium assistance for ESRD patients.
FMD said it received a subpoena on Jan. 3 from the U.S. Attorney for
the District of Massachusetts seeking information related to the
premium assistance programme, adding it was cooperating with the
(Reporting by Emma Thomasson; editing by John Stonestreet)
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.